Kymera Therapeutics (NASDAQ:KYMR) Insider Jared Gollob Sells 4,895 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Jared Gollob sold 4,895 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $85.30, for a total transaction of $417,543.50. Following the sale, the insider owned 117,134 shares in the company, valued at $9,991,530.20. This represents a 4.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jared Gollob also recently made the following trade(s):

• On Monday, March 2nd, Jared Gollob sold 5,613 shares of Kymera Therapeutics stock. The stock was sold at an average price of $88.93, for a total transaction of $499,164.09.
• On Monday, December 8th, Jared Gollob sold 49,307 shares of Kymera Therapeutics stock. The shares were sold at an average price of $88.67, for a total transaction of $4,372,051.69.

Kymera Therapeutics Stock Performance

Shares of Kymera Therapeutics stock traded down $0.24 during midday trading on Wednesday, hitting $86.11. The company’s stock had a trading volume of 1,043,150 shares, compared to its average volume of 845,289. Kymera Therapeutics, Inc. has a 1-year low of $19.44 and a 1-year high of $103.00. The stock has a 50-day simple moving average of $78.69 and a 200-day simple moving average of $66.27.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The business had revenue of $2.87 million during the quarter, compared to analysts’ expectations of $14.80 million. During the same period in the prior year, the company posted ($0.88) earnings per share. The firm’s revenue was down 60.8% on a year-over-year basis. On average, sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Analyst Ratings Changes

KYMR has been the topic of a number of analyst reports. Truist Financial increased their price objective on Kymera Therapeutics from $80.00 to $116.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Thursday, January 22nd. Royal Bank Of Canada reissued an “outperform” rating and issued a $108.00 price target on shares of Kymera Therapeutics in a research report on Thursday, February 26th. Morgan Stanley restated an “overweight” rating and issued a $123.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, February 26th. Finally, Oppenheimer raised their target price on shares of Kymera Therapeutics from $67.00 to $120.00 and gave the company an “outperform” rating in a research note on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Kymera Therapeutics has an average rating of “Moderate Buy” and an average target price of $119.50.

Institutional Investors Weigh In On Kymera Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of KYMR. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Kymera Therapeutics by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock valued at $849,000 after acquiring an additional 1,833 shares during the period. Millennium Management LLC boosted its position in shares of Kymera Therapeutics by 340.4% during the first quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock worth $13,972,000 after buying an additional 394,562 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Kymera Therapeutics by 121.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock worth $24,535,000 after buying an additional 491,737 shares in the last quarter. PNC Financial Services Group Inc. raised its position in Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after buying an additional 770 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Kymera Therapeutics by 5.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,193,112 shares of the company’s stock valued at $52,075,000 after acquiring an additional 59,347 shares in the last quarter.

Key Headlines Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: UBS raised its price target to $128 and maintained a Buy rating, implying meaningful upside vs. the current level — this is a material analyst catalyst that can support upside interest. UBS price target raise
• Positive Sentiment: Analyst coverage and commentary highlight Kymera’s strong cash position (~$1.6B) and advancing degraders (KT‑621, KT‑579) into mid‑stage trials — these program milestones (2026–2027 catalysts) underpin medium‑term upside. Seeking Alpha pipeline write-up
• Positive Sentiment: Recent press roundups note broad analyst bullishness on select healthcare names including Kymera, which can help sustain investor interest from institutions and momentum traders. Globe and Mail analyst roundup
• Neutral Sentiment: Fundamentals remain mixed: recent quarterly results included a revenue shortfall and wider losses, which keep near‑term valuation sensitive to execution and clinical readouts. (Context referenced in analyst coverage above.) Seeking Alpha: financial context
• Negative Sentiment: Large director sale: Director Bruce Booth sold 81,866 shares (~$7.38M) — a ~10.8% reduction in his holding — which is a notable insider disposition that may create near‑term selling pressure or prompt investor questions about timing. Bruce Booth Form 4
• Negative Sentiment: Multiple executive sales: CFO Bruce Jacobs, COO Jeremy Chadwick and insider Jared Gollob completed several transactions across March 2–4 totaling tens of thousands of shares at prices in the mid‑$80s to ~$90 — cumulative insider selling raises short‑term supply concerns. Insider filings

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.